On Demand 2026 Saturday AM General Sessions

This course contains the following sessions from Saturday's morning program:

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of X AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Understand the foundational overview of the structure, function, and immunologic influence of the human microbiome across the lifespan, with emphasis on mechanisms relevant to allergic disease.
  • Examine how perinatal factors, feeding practices, antibiotics, environmental biodiversity, and viral exposures shape microbial development and influence risk for asthma, food allergy, and atopic dermatitis.
  • Explore evidence-based and emerging strategies to modulate the gut, skin, and airway microbiome, including probiotics, diet, and microbial therapies. Learn which approaches are ready for clinical use and how they may influence allergy prevention and management.
  • Analyze existing data on long-acting anti-IL-5 therapies in CRSwNP and asthma.
  • Explain and position bispecific antibodies (eg, anti-IL13+anti-TSLP) in the treatment of atopic disease.
  • Explore BTK inhibition as a target for multiple atopic diseases.
  • Examine the utility of blocking the co-stimulatory pathway between T-cells and APCs.
  • Evaluate targeting KIT for CSU and other mast cell-dependent diseases.
  • Analyze STAT6 as a novel target for atopic disease.
  • Distinguish emerging selective arachidonic acid pathway inhibitors from legacy agents.
  • Summarize the available topical therapy from topical corticosteroids, calcineurin inhibitors, PDE4, JAK and aryl hydrocarbons including where on the body to use each, which patients are best to use them on, frequency of use and mitigation of side effects.
  • Assess the hierarchy of the currently available systemic therapies, including JAK inhibitors and biologics, and whom to select for each. Recognize the adverse effects being noticed in our current therapies.
  • Understand the direction for personalized medicine that AD skin care is moving, including use of the biomarkers, OX40, OX40L, dual target biologics and biosimilars.
  • Identify common FPIES symptoms in children and adults; Recognize emerging global FPIES triggers and address when they should be introduced into the diet.
  • Discuss the role of oral food challenges in assessing for FPIES resolution and identify appropriate patient selection criteria. Describe evidence-based protocols for conducting safe and effective oral food challenges, including risk mitigation strategies and emergency preparedness.
  • Identify nutrition risks associated with FPIES in children and apply appropriate solutions to prevent or correct poor nutrition.
  • Determine the pathophysiology, risk factors, diagnosis, and prognosis of alpha-gal. This session will review the presentation of perioperative anaphylaxis, common culprits, and diagnosis and management.
  • Address both exercise-induced anaphylaxis and food-dependent exercise-induced anaphylaxis, including presentation, diagnosis, and management.
  • Differentiate true idiopathic anaphylaxis from unrecognized triggers and mast cell disorders and implement evidence-based strategies for acute management and long-term prophylaxis
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary

Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
  • 7.25 CBRN
Course opens: 
11/24/2026
Course expires: 
12/31/2027
Rating: 
0

Cherie Y. Zachary, MD, FACAAI
Susan V. Lynch, PhD
Kirsi M. Jarvinen-Seppo, MD, PhD
Stuart Turvey, MBBS, DPhil, FRCPC
Jared Darveaux, MD, FACAAI
Nicole M. Chase, MD, FACAAI, FAAP
Daniel J. Jackson, MD, FACAAI
Nicola A. Hanania, MD, MS
Jason E. Hawkes, MD, MS, FAAD
Raj Chovatiya, MD, PhD, MSCI
Matthew P. Giannetti, MD
Jonathan M. Spergel, MD, PhD, FACAAI
Larry Borish, MD, FACAAI
Dylan T. Timberlake, MD, FACAAI
Peter A. Lio, MD, FAAD
Mark Boguniewicz, MD, FACAAI
Vikash Oza, MD, FAAD
Theresa A. Bingemann, MD, FACAAI
Mary Grace Baker, MD, MS
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Sara Anvari, MD, MSc, FACAAI
Marion E. Groetch, MS, RD
Michael Pistiner, MD MMSc, FACAAI
Amber Hardeman, MD, MPH, MBA
Collette Maria Tilly, MD
Scott P. Commins, MD, PhD
Jerold H. Levy, MD
Jay A. Lieberman, MD, FACAAI

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
  • 7.25 CBRN
Please login or create an account to take this course.